Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronically inhaled salmeterol improves pulmonary function in heart failure.

Tien M H Ng1, Mark A Munger, William L Lombardi

  • 1Department of Pharmacy Practice, University of Utah Health Sciences Center, Salt Lake City, UT, USA. tng@unmc.edu

Journal of Cardiovascular Pharmacology
|June 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrocardiographic Changes After Percutaneous Coronary Intervention for Chronic Total Occlusion.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Comparative validation of risk scores for in-hospital complications following chronic total occlusion percutaneous coronary intervention.

American heart journal·2026
Same author

Current State of Clinical Care of People With Cystic Fibrosis.

Pharmacotherapy·2026
Same author

Outcomes of Same-Day Discharge in Chronic Total Occlusion Percutaneous Coronary Intervention.

The American journal of cardiology·2026
Same author

Protamine for Coronary Perforation in Chronic Total Occlusion Percutaneous Coronary Intervention.

Journal of cardiovascular pharmacology·2026
Same author

An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations.

Open forum infectious diseases·2026

Inhaled salmeterol improved FEV1 in heart failure patients but did not increase neurohormonal activity or ventricular ectopy. This study suggests potential benefits for pulmonary function, though rate-pressure product increases warrant further investigation.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Inhaled beta-agonists are frequently used for exercise intolerance in heart failure.
  • However, data on their safety and efficacy in this population is limited.

Purpose of the Study:

  • To evaluate the effect of chronic inhaled salmeterol on pulmonary function.
  • To assess the safety of salmeterol regarding neurohormonal systems and ventricular ectopy in heart failure patients.

Main Methods:

  • A prospective, randomized, double-blind, placebo-controlled 14-day crossover study.
  • 8 symptomatic heart failure subjects with LVEF <40% and FEV1 ≤80% were included.
  • Primary endpoint was FEV1; secondary endpoints included FVC, neurohormones, and ectopy.

Related Experiment Videos

Main Results:

  • Salmeterol significantly improved FEV1 by 6% compared to placebo (p=0.01).
  • No significant differences were observed in FVC, FEF25-75, or PEFR.
  • Salmeterol increased rate-pressure product by 5% (p=0.04) but did not elevate neurohormones or ventricular ectopy.

Conclusions:

  • Inhaled salmeterol improves FEV1 in heart failure patients without adverse effects on neuroactivation or ventricular ectopy.
  • Minor increases in rate-pressure product were observed, requiring further clinical evaluation.
  • Salmeterol's prolonged half-life in heart failure may lead to steady-state accumulation.